4/16/11

Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death

Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death




While treatment is believed to influence diseaseoutcome, the wide variation in published survival andremission rates among chronic myeloid leukemia (CML)patients demonstrates that the effectiveness oftreatment appears to be modified by patientcharacteristics, disease features, and diseasemanagement approaches. Future improvements in thetreatment of CML are dependent on our ability todistinguish between patients who are likely to havelong-term disease free survival and those who are not.Between June 1982 and December 2002, 234 patientswith CML in first chronic phase (CP) were treated atthe City of Hope National Medical Center with anallogeneic blood or marrow transplant (Allo-BMT)using histocompatible sibling donors. Thisretrospective case-s





List Price: $ 86.67

Price: $ 86.67

Leukemia Problems Remedies | FIGHT CANCER INFO
Leukemia — Comprehensive overview covers symptoms, causes, risk factors, treatment of this blood-related cancer.
Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death



Find More Leukemia Relapse Products

Orignal From: Blood/Marrow Transplantation for Treatment of ChronicMyeloid Leukemia: Identifying Predictors of Cytogenetic Relapse and Death

No comments:

Post a Comment